KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsReceivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Gsk (GSK) Leases (2019 - 2025)

Historic Leases for Gsk (GSK) over the last 7 years, with Q3 2025 value amounting to $1.1 billion.

  • Gsk's Leases fell 235.15% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year decrease of 235.15%. This contributed to the annual value of $1.1 billion for FY2024, which is 721.1% down from last year.
  • As of Q3 2025, Gsk's Leases stood at $1.1 billion, which was down 235.15% from $1.1 billion recorded in Q2 2025.
  • Over the past 5 years, Gsk's Leases peaked at $1.2 billion during Q4 2023, and registered a low of $134.2 million during Q1 2022.
  • Moreover, its 5-year median value for Leases was $1.0 billion (2025), whereas its average is $944.8 million.
  • Its Leases has fluctuated over the past 5 years, first tumbled by 8769.78% in 2022, then surged by 49424.14% in 2023.
  • Over the past 5 years, Gsk's Leases (Quarter) stood at $997.5 million in 2021, then decreased by 19.22% to $805.8 million in 2022, then skyrocketed by 44.32% to $1.2 billion in 2023, then decreased by 6.63% to $1.1 billion in 2024, then decreased by 1.85% to $1.1 billion in 2025.
  • Its Leases stands at $1.1 billion for Q3 2025, versus $1.1 billion for Q2 2025 and $1.0 billion for Q1 2025.